List view / Grid view
Professor Ulrich G Steidl received the National Institute of Cancer's Outstanding Investigator Award to study myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML).
Ali Shilatifard’s article explains how investment in institutes performing molecular research is essential, as it is the foundation for all attempts to combat COVID-19 and other future pandemics.
Central to reproducibility in biomedical research is the ability to use well-characterised and defined reagents. The CPTAC Antibody Portal serves as a National Cancer Institute community resource that provides access to many standardised renewable affinity reagents to cancer-associated targets and accompanying characterisation data. Nikki Withers spoke to Dr Tara Hiltke…
Scientists utilise computational biology techniques in a bid to enable doctors to use targeted therapies for cancer patients.
Immunotherapy drug candidate could be potent weapon against neuroblastoma and other paediatric malignancies...
Researchers have used CRISPR to stop the expression of individual genes in cancer cells, by knocking out every known protein-encoding gene in the human genome...
Researchers have found a higher than expected prevalence of cancer at baseline screening in individuals with Li-Fraumeni syndrome...
Phase 2 trial to explore targeted therapies for children with solid tumours that harbour specific genetic mutations which have progressed during or after standard therapy...
For nearly two decades researchers have sought a way to target an oestrogen receptor in the hope they could improve breast cancer survival, but an article contends that the effort may never pan out.
Viruses are notorious for taking over their host's operations and using them to their own advantage. But few human viruses make themselves quite as cozy as the Epstein-Barr virus, which can be found in an estimated 9/10 humans without causing any ill effects. That is, until this virus causes mononucleosis…
Scientists will develop and test promising new molecules for targeting RAS, one of the most common driving mutations in aggressive, hard to treat cancers including pancreatic and lung cancer.
11 July 2016 | By Victoria White, Digital Content Producer
An international project to develop a large, globally accessible, bank of new cancer models for the research community launches today...
6 June 2016 | By Victoria White, Digital Content Producer
The Genomic Data Commons (GDC), a unified data system that promotes sharing of genomic and clinical data between researchers, launched today...
